MA55767A - Forme cristalline s4 d'un inhibiteur de plk4 (1r,2s)-(e)-2-(3-(4-((cis-2,6-diméthylmorpholino)méthyl)styryl)- 1 h-imidazol-6- yl)-5'-méthoxyspiro[cyclopropane-l,3'-indolin]-2'-one fumarate - Google Patents

Forme cristalline s4 d'un inhibiteur de plk4 (1r,2s)-(e)-2-(3-(4-((cis-2,6-diméthylmorpholino)méthyl)styryl)- 1 h-imidazol-6- yl)-5'-méthoxyspiro[cyclopropane-l,3'-indolin]-2'-one fumarate

Info

Publication number
MA55767A
MA55767A MA055767A MA55767A MA55767A MA 55767 A MA55767 A MA 55767A MA 055767 A MA055767 A MA 055767A MA 55767 A MA55767 A MA 55767A MA 55767 A MA55767 A MA 55767A
Authority
MA
Morocco
Prior art keywords
methoxyspiro
dimethylmorpholino
indolin
cyclopropane
styryl
Prior art date
Application number
MA055767A
Other languages
English (en)
French (fr)
Inventor
Mark Robert Bray
Sze-Wan Li
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of MA55767A publication Critical patent/MA55767A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA055767A 2019-04-24 2020-04-23 Forme cristalline s4 d'un inhibiteur de plk4 (1r,2s)-(e)-2-(3-(4-((cis-2,6-diméthylmorpholino)méthyl)styryl)- 1 h-imidazol-6- yl)-5'-méthoxyspiro[cyclopropane-l,3'-indolin]-2'-one fumarate MA55767A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962837858P 2019-04-24 2019-04-24

Publications (1)

Publication Number Publication Date
MA55767A true MA55767A (fr) 2022-03-02

Family

ID=72940551

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055767A MA55767A (fr) 2019-04-24 2020-04-23 Forme cristalline s4 d'un inhibiteur de plk4 (1r,2s)-(e)-2-(3-(4-((cis-2,6-diméthylmorpholino)méthyl)styryl)- 1 h-imidazol-6- yl)-5'-méthoxyspiro[cyclopropane-l,3'-indolin]-2'-one fumarate

Country Status (15)

Country Link
US (1) US12325700B2 (enExample)
EP (1) EP3959209A4 (enExample)
JP (1) JP7705351B2 (enExample)
KR (1) KR20220004102A (enExample)
CN (1) CN113966330B (enExample)
BR (1) BR112021021106A2 (enExample)
CA (1) CA3137191A1 (enExample)
EA (1) EA202192903A1 (enExample)
IL (1) IL287394A (enExample)
MA (1) MA55767A (enExample)
MX (1) MX2021012993A (enExample)
SA (1) SA521430647B1 (enExample)
SG (1) SG11202111003UA (enExample)
TW (1) TWI862582B (enExample)
WO (1) WO2020215155A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023013225A (es) 2021-05-11 2024-01-15 Oric Pharmaceuticals Inc Inhibidores de la cinasa 4 similar a polo.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7205328B2 (en) 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
DE102005005395A1 (de) 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
GB0606234D0 (en) 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
US20110201818A1 (en) 2007-09-25 2011-08-18 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
JP2011506494A (ja) 2007-12-21 2011-03-03 ユニバーシティ・ヘルス・ネットワーク 癌の治療に有用なキナーゼ阻害剤としてのインダゾリル、ベンズイミダゾリル、ベンゾトリアゾリル置換インドルモン誘導体
EP2417127B1 (en) 2009-04-06 2014-02-26 University Health Network Kinase inhibitors and method of treating cancer with same
ES2660146T3 (es) 2009-04-29 2018-03-21 Nerviano Medical Sciences S.R.L. Sales del inhibidor de cdk
PT2556071T (pt) 2010-04-06 2016-11-22 Univ Health Network Inibidores de quinase e seus usos no tratamento de cancro
WO2012000103A1 (en) 2010-07-02 2012-01-05 University Health Network Methods of targeting pten mutant diseases and compositions therefor
WO2012048411A1 (en) 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
KR20130105675A (ko) 2010-11-25 2013-09-25 라티오팜 게엠베하 아파티닙의 신규 염 및 다형
US9580390B2 (en) 2011-10-12 2017-02-28 University Health Network Indazole compounds as kinase inhibitors and method of treating cancer with same
ES2908200T3 (es) 2013-10-18 2022-04-28 Univ Health Network Tratamiento para el cáncer de páncreas
HRP20190564T1 (hr) 2013-10-18 2019-05-17 University Health Network Sol i kristalni oblici inhibitora plk-4

Also Published As

Publication number Publication date
KR20220004102A (ko) 2022-01-11
TWI862582B (zh) 2024-11-21
JP2022530028A (ja) 2022-06-27
BR112021021106A2 (pt) 2021-12-14
MX2021012993A (es) 2021-12-10
JP7705351B2 (ja) 2025-07-09
CN113966330B (zh) 2024-09-13
WO2020215155A8 (en) 2020-11-26
CN113966330A (zh) 2022-01-21
US20220204494A1 (en) 2022-06-30
US12325700B2 (en) 2025-06-10
CA3137191A1 (en) 2020-10-29
WO2020215155A1 (en) 2020-10-29
EA202192903A1 (ru) 2022-02-09
IL287394A (en) 2021-12-01
SA521430647B1 (ar) 2024-01-27
EP3959209A4 (en) 2022-12-28
EP3959209A1 (en) 2022-03-02
TW202104216A (zh) 2021-02-01
SG11202111003UA (en) 2021-11-29
AU2020264143A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
EP4057920C0 (en) TRANSCATHETER INTRODUCTION OF A MEDICAL IMPLANT
CL2019003188A1 (es) Sales de inhibidor de pi3k y procesos de preparación. (divisional solicitud 201702179)
EP3768187A4 (en) FAST AND PRECISE TOOL CHANGE MECHANISM FOR INTRAOCULAR ROBOTIC SURGICAL SYSTEMS
HUS000506I2 (hu) Tigilanol tiglát, geometriai izomerjei, sztereoizomerjei és gyógyászatilag, mezõgazdaságilag vagy kártevõirtóként elfogadható sói
SMT201200052B (it) Dispositivo per l'erogazione di lenti intraocularidotato di una cartuccia con un rivestimento inter no
EP3943417A4 (en) STORAGE ROBOT
SMP201000002B (it) Sali dell'inibitore di chinasi janus (R)-3-(4-(7H-pirrolo[2,3-D]pirimidin-4-IL)-1H-pirazoli-1-IL)-3-ciclopentilpropanonitrile
MA52424A (fr) Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide
EP3927729A4 (en) Therapeutic antibody formulation
DOP2018000190A (es) Nueva forma cristalina de sal de 1–(5–(2,4–difluorfenil)–1–((3–fluorfenil)sulfonil)–4–metoxi–1h–pirrol–3–il)–n–metilmetanamina
EP3481428A4 (en) ADHESIVE ORAL SOLDERED FOILS FOR CARING THE MOUTH CARE
EP3849562A4 (en) COMBINATION COMPOSITIONS WITH A BETA-LACTAMASE INHIBITOR
MA55976A (fr) Formes cristallines de n-(5-(5-((1r, 2s)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl) imidazo [1,2-a] pyridine-3-carboxamide
EP3986415A4 (en) IBOGAIN FORMULATIONS
EP3992176A4 (en) EP2 ANTAGONIST
ITGE20030014A1 (it) Macchina automatica con attivazione a moneta per la fabbricazione e la distribuzione estemporanea di dosi
IL287394A (en) In the s4 crystal form of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-(cis-2,6-dimethylmorpholino)methyl)styrol)- 1 h-imidazol-6-yl)-5' -Methoxyspirio[cyclopropane-1,3'-indoline]-2'-one fumarate
EP3932977A4 (en) SEALING FILM
EP3903723A4 (en) Dental implant handset
EP3794015A4 (en) ACTIVATING AGENT
HK40070200A (en) Crystal form s4 of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate
EP3302466A4 (en) 3-(phenyl)-n-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of cftr protein mediated diseases
MA53009A (fr) Agents inhibiteurs d'ask1
EP3937991A4 (en) STERILIZER FOR PROSTHETIC ACCESSORIES
EP3953677A4 (en) TISSUE EMBEDDED CASSETTE WITH SHIELDING